Table 4.

Relative risks of incident hip and pelvic fractures among ONTARGET and TRANSCEND participants from year 2 to the last visit at 4.2 years with baseline albuminuria status that progressed (− → +), regressed (+ → −), or stayed the same at 2 years of follow-up compared with participants with no albuminuria at baseline or year 2 of follow-up

VariablesM1: HR (95% CI)M2: HR (95% CI)M3: HR (95% CI)
ALB +/− versus −/−1.48 (0.80–2.76), P=0.211.31 (0.70–2.44), P=0.391.24 (0.66–2.33), P=0.50
ALB −/+ versus −/−2.06 (1.28–3.32), P=0.0031.70 (1.05–2.75), P=0.031.61 (0.99–2.62), P=0.05
ALB +/+ versus −/−1.79 (1.13–2.83), P=0.011.70 (1.07–2.70), P=0.021.52 (0.93–2.47), P=0.09
Age (yr)1.09 (1.07–1.12), P≤0.0011.09 (1.07–1.11), P≤0.001
Female versus male2.40 (1.75–3.27), P≤0.0012.41 (1.70–3.43), P≤0.001
Asian versus European0.98 (0.63–1.52), P=0.920.87 (0.55–1.37), P=0.54
Other versus European0.88 (0.55–1.40), P=0.580.87 (0.54–1.39), P=0.55
BMI<20 versus ≥302.42 (0.99–5.89), P=0.05
BMI=20 to <30 versus BMI≥301.43 (0.97–2.11), P=0.07
History of diabetes1.25 (0.88–1.78), P=0.21
History of CVD1.09 (0.62–1.91), P=0.76
Current versus never smoker1.28 (0.74–2.22), P=0.38
Former versus never smoker0.93 (0.65–1.34), P=0.69
Year 2 eGFR MDRD<30 versus ≥601.96 (0.91–4.24), P=0.09
Year 2 eGFR MDRD=30 and <45 versus ≥600.98 (0.58–1.67), P=0.95
Year 2 eGFR MDRD≥45 and <60 versus ≥600.88 (0.60–1.30), P=0.53
Alcohol ≥3 drinks/d (21 drinks/wk)1.16 (0.37–3.68), P=0.80
Physical activity less than once a week0.92 (0.65–1.28), P=0.61
Rapid decline in eGFR≥5%/yr from baseline to year 21.47 (1.05–2.04), P=0.02
  • eGFR is ml/min per 1.73m2. ONTARGET, Ongoing Telmisartan Alone and in combination with Ramipril Global End Point Trial; TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Intolerant Subjects with Cardiovascular Disease; M, model; HR, hazard ration; CI, confidence interval; ALB, albuminuria; BMI, body mass index; CVD, coronary artery disease, stroke, or peripheral arterial disease; eGFR, estimated GFR; MDRD, Modification of Diet in Renal Disease.